Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Federated Investors Inc. PA

Federated Investors Inc. PA reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,118 shares of the biopharmaceutical company’s stock after selling 238 shares during the quarter. Federated Investors Inc. PA’s holdings in Regeneron Pharmaceuticals were worth $2,022,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of REGN. Assenagon Asset Management S.A. purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $295,000. Swiss National Bank increased its holdings in Regeneron Pharmaceuticals by 27.5% during the 1st quarter. Swiss National Bank now owns 275,300 shares of the biopharmaceutical company’s stock valued at $106,682,000 after acquiring an additional 59,300 shares in the last quarter. World Asset Management Inc increased its holdings in Regeneron Pharmaceuticals by 20.8% during the 1st quarter. World Asset Management Inc now owns 8,224 shares of the biopharmaceutical company’s stock valued at $3,187,000 after acquiring an additional 1,415 shares in the last quarter. Morse Asset Management Inc purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $3,335,000. Finally, British Columbia Investment Management Corp increased its holdings in Regeneron Pharmaceuticals by 33.2% during the 1st quarter. British Columbia Investment Management Corp now owns 56,099 shares of the biopharmaceutical company’s stock valued at $21,739,000 after acquiring an additional 13,998 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/09/25/regeneron-pharmaceuticals-inc-regn-shares-sold-by-federated-investors-inc-pa.html.

A number of brokerages have recently commented on REGN. Leerink Swann reiterated an “outperform” rating and set a $573.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. Raymond James Financial, Inc. reiterated an “outperform” rating and set a $547.00 price target (up from $475.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. Bank of America Corporation restated a “buy” rating and issued a $593.00 target price (up from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. BMO Capital Markets restated a “market perform” rating and issued a $484.00 target price (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Sanford C. Bernstein downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $410.00 to $480.00 in a report on Monday, June 26th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $490.03.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 432.72 on Monday. The stock has a market capitalization of $45.88 billion, a price-to-earnings ratio of 43.41 and a beta of 1.65. The firm’s 50-day moving average is $468.97 and its 200-day moving average is $447.18. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the previous year, the business posted $2.82 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.89 earnings per share for the current fiscal year.

In related news, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at approximately $4,296,456.81. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found

A number of other large investors have also bought and sold shares of REGN. Assenagon Asset Management S.A. purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $295,000. Swiss National Bank increased its holdings in Regeneron Pharmaceuticals by 27.5% during the 1st quarter. Swiss National Bank now owns 275,300 shares of the biopharmaceutical company’s stock valued at $106,682,000 after acquiring an additional 59,300 shares in the last quarter. World Asset Management Inc increased its holdings in Regeneron Pharmaceuticals by 20.8% during the 1st quarter. World Asset Management Inc now owns 8,224 shares of the biopharmaceutical company’s stock valued at $3,187,000 after acquiring an additional 1,415 shares in the last quarter. Morse Asset Management Inc purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $3,335,000. Finally, British Columbia Investment Management Corp increased its holdings in Regeneron Pharmaceuticals by 33.2% during the 1st quarter. British Columbia Investment Management Corp now owns 56,099 shares of the biopharmaceutical company’s stock valued at $21,739,000 after acquiring an additional 13,998 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/09/25/regeneron-pharmaceuticals-inc-regn-shares-sold-by-federated-investors-inc-pa.html.

A number of brokerages have recently commented on REGN. Leerink Swann reiterated an “outperform” rating and set a $573.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. Raymond James Financial, Inc. reiterated an “outperform” rating and set a $547.00 price target (up from $475.00) on shares of Regeneron Pharmaceuticals in a report on Thursday, June 22nd. Bank of America Corporation restated a “buy” rating and issued a $593.00 target price (up from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. BMO Capital Markets restated a “market perform” rating and issued a $484.00 target price (up from $421.00) on shares of Regeneron Pharmaceuticals in a report on Friday, July 21st. Finally, Sanford C. Bernstein downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $410.00 to $480.00 in a report on Monday, June 26th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $490.03.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 432.72 on Monday. The stock has a market capitalization of $45.88 billion, a price-to-earnings ratio of 43.41 and a beta of 1.65. The firm’s 50-day moving average is $468.97 and its 200-day moving average is $447.18. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter in the previous year, the business posted $2.82 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.89 earnings per share for the current fiscal year.

In related news, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the sale, the senior vice president now owns 9,099 shares of the company’s stock, valued at approximately $4,296,456.81. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total value of $94,700.34. Following the completion of the sale, the chief financial officer now directly owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold a total of 85,968 shares of company stock worth $40,699,948 in the last quarter. 10.40% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.